Swipe om te navigeren naar een ander artikel
Jacobien M. Kieffer and Tjeerd J. Postma—Shared first authorship.
Collaborators of the CI-PeriNomS Groups are listed in “Appendix”.
To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20).
Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors. Additional models were investigated with exploratory factor analysis (EFA). Known groups validity was evaluated where justified.
CFA could not confirm the two hypothesized models (Model 1: CFI < 0.926; TLI < 0.914; RMSEA > 0.077 and Model 2: CFI < 0.906; TLI < 0.887; RMSEA > 0.105) in any of the three samples. Including a general factor to these two hypothesized models to produce a bi-factor model also did not yield satisfactory results. Using EFA, we identified four different factor structures in the three samples that were unstable due to cross loadings of the items. When scoring the QLQ-CIPN20 as a simple, additive checklist evidence was found for known groups validity in the first two samples based on Common Toxicity Criteria (CTC-AE), and in the third sample based on exposure to CIPN-inducing chemotherapy.
Neither CFA nor EFA yielded support for a stable subscale structure for the QLQ-CIPN20. Scoring the questionnaire as a simple additive checklist results in acceptable validity.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013). Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. Journal of Clinical Oncology, 31(21), 2699–2707. CrossRefPubMed
Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol, 7(11), 903–909. CrossRefPubMed
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et al. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32(18), 1941–1967. CrossRefPubMed
Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., et al. (2009). Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC. Support Care Center, 17(12), 1483–1491. CrossRef
Land, S., Kopec, J., Cecchini, R., Ganz, P., Wieand, H. S., Colangelo, L., et al. (2007). Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal of Clinical Oncology, 25(16), 2205–2211. CrossRefPubMed
Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J., et al. (2006). Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. Journal of supportive oncology, 4, W1–W8.
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135–1139. CrossRefPubMed
Wolf, S., Barton, D., Qin, R., Wos, E., Sloan, J., Liu, H., et al. (2012). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Supportive Care in Cancer, 20(3), 625–632. CrossRefPubMed
Lavoie Smith, E., Barton, D., Qin, R., Steen, P., Aaronson, N., & Loprinzi, C. (2013). Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Quality of Life Research, 22(10), 2787–2799. CrossRefPubMedPubMedCentral
Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., et al. (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Annals of Oncology, 24(2), 454–462. CrossRefPubMed
Hausheer, F. H., Kanter, P., Cao, S., Haridas, K., Seetharamulu, P., Reddy, D., et al. (1998). Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Seminars in Oncology, 25(5), 584–599. PubMed
Reilly, R. T. (2004). BNP-7787 (BioNumerik/Baxter Oncology/Grelan). IDrugs, 7(1), 64–69. PubMed
Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., et al. (2000). Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. International Journal of Radiation Oncology * Biology *Physics, 47(1), 13–47. CrossRef
Muthén, L. K., & Muthén, B. O. (1998–2010). Mplus User’s Guide (6th ed.). Los Angeles, CA: Muthén & Muthén.
Muthen, B., du Toit, S., & Spisic, D. (1997). Robust inference using weighted least squares and quadratic estimating equation in latent variable modeling with categorical and continuous outcomes. Retrieved January 8, 2015, from http://www.statmodel.com/bmuthen/articles/Article_075.pdf
Schermelleh-Engel, K., Moosbrugger, H., & Muller, H. (2003). Evaluating the fit of structural equation models: Tests of significance and descriptive goodness-of-fit measures. Methods of Psychological Research-Online, 8, 23–74.
Ferguson, E., & Cox, T. (1993). Exploratory factor analysis: A users’guide. International Journal of Selection and Assessment, 1(2), 84–94. CrossRef
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group and of the Quality of Life Unit. (2001). EORTC QLQ- C30 Scoring Manual (3rd ed.). Brussels EORTC.
Šidák, Z. (1967). Rectangular confidence regions for the means of multivariate normal distributions. Journal of the American Statistical Association, 62(318), 626–633.
Cohen, J. (1977). Statistical power analysis for the behavioural sciences (revised ed.). New York: Academic Press
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592. PubMed
Egan, M., Burke, E., Meskell, P., MacNeela, P., & Dowling, M. (2015). Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. Journal of Research in Nursing. doi: 10.1177/1744987115574296.
Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., et al. (2014). Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 32(10), 997–1005. CrossRefPubMed
Fayers, P., & Hand, D. (2002). Causal variables, indicator variables and measurement scales: An example from quality of life. Journal of the Royal Statistical Society: Series A (Statistics in Society), 165(2), 233–253. CrossRef
Ruland, C. M., Holte, H. H., Røislien, J., Heaven, C., Hamilton, G. A., Kristiansen, J., et al. (2010). Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. Journal of the American Medical Informatics Association, 17(4), 403–410. CrossRefPubMedPubMedCentral
Kluetz, P. G., Slagle, A., Papadopoulos, E., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research, 22(7), 1553–1558. CrossRefPubMed
- Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)
Jacobien M. Kieffer
Tjeerd J. Postma
Lonneke van de Poll-Franse
Jan J. Heimans
Neil K. Aaronson
In Collaboration with the CI-PeriNomS Group
- Springer International Publishing